Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
|
|
InspireMD, Inc. (NSPR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/08/2023 |
8-K
| Quarterly results |
| 05/16/2023 |
8-K
| Quarterly results |
| 11/08/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/11/2021 |
8-K
| Quarterly results |
| 11/09/2020 |
8-K
| Quarterly results |
| 08/05/2020 |
8-K
| Quarterly results |
| 05/12/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/06/2019 |
8-K
| Quarterly results |
| 05/14/2019 |
8-K
| Quarterly results |
| 02/19/2019 |
8-K
| Quarterly results |
| 11/06/2018 |
8-K
| Quarterly results |
| 08/07/2018 |
8-K
| Quarterly results |
| 05/07/2018 |
8-K
| Quarterly results |
| 02/14/2018 |
8-K
| Quarterly results |
| 11/07/2017 |
8-K
| Quarterly results|
Docs:
|
"InspireMD Announces Third Quarter 2017 Results; CGuard™ Revenue Increases 90% Versus Same Period Last year Tel Aviv, Israel—November 7, 2017 - InspireMD, Inc. , a leader in Embolic Prevention Systems / thrombus management technologies and neurovascular devices, today announced preliminary results for the third quarter ending September 30, 2017. James Barry, PhD, Chief Executive Officer of InspireMD, commented, “Not only did we achieve a 90% year-over-year increase in sales of CGuard™ EPS for the third quarter of 2017, but we also achieved a 22% sequential increase versus the second quarter of 2017. We achieved these strong results, even though the third quarter tends to be seasonally weak. We believe this growth is evidence that our new distribution and key opinion leader strat..." |
|
| 08/08/2017 |
8-K
| Quarterly results |
| 05/09/2017 |
8-K
| Form 8-K - Current report |
| 02/21/2017 |
8-K
| Form 8-K - Current report |
| 11/14/2016 |
8-K
| Quarterly results|
Docs:
|
"CONSOLIDATED STATEMENTS OF OPERATIONS Three months ended Nine months ended September 30, September 30, 2016 2015 2016 2015 Revenues $ 469 $ 632 $ 1,572 $ 1,794 Cost of revenues 438 543 1,414 1,954 Gross Profit 31 89 158 Operating Expenses: Research and development 289 781 1,068 2,880 Selling and marketing 329 588 1,116 2,600 General and administrative 1,183 1,713 3,932 5,270 Restructuring and impairment - 418 - 964 Total operating expenses 1,801 3,500 6,116 11,714 Loss from operations Financial expenses 237 228 638 856 Loss before tax expenses Tax expenses - 2 1 1 Net Loss $ $ $ $ Net loss per share – basic and diluted $ $ $ $ Weighted average number of shares of common stock used in computing net loss per share – basic and diluted 2,341,807 305,240 1,034,943 270,120 5 CONSOLIDATED BA...",
"InspireMD Announces CGuard TM Embolic Prevention System Commercialization Approval in Russia BOSTON, MA – November 14, 2016 – InspireMD, Inc. , a leader in embolic prevention systems , neurovascular devices and thrombus management technologies, today announced that it has received regulatory approval to commercialize the CGuard TM Embolic Prevention System for the treatment of carotid artery disease in Russia. The approval was granted by Russia’ s Federal Service for Surveillance in Healthcare . According to a presentation titled “Carotid Stenting and Surgery in 2016 in Russia” at Novosibirsk Research Institute of Circulation Pathology, the Management Board Report of Russian Society of Angiology and Vascular Surgeons reported that Russia, among all European countries, has the highest rate ..." |
|
| 08/09/2016 |
8-K
| Quarterly results |
| 05/10/2016 |
8-K
| Quarterly results|
Docs:
|
"InspireMD Reports Financial Results for the First Quarter Ended March 31, 2016 BOSTON, MA – May 10, 2016 – InspireMD, Inc. , a leader in embolic prevention systems , neurovascular devices and thrombus management technologies, today announced its financial and operating results for the first quarter ended March 31, 2016. During the first quarter, InspireMD announced initiatives to support ongoing commercial operations and development programs. Key activities include announced: · Completed private placement and public offering; · Strengthened Board of Directors with appointment of Isaac Blech as Vice Chairman; and · Continued operational and financial alignment, with ongoing implementation of a comprehensive cash management program. Sol Barer, Chairman of the Board of In..." |
|
| 03/30/2016 |
8-K
| Quarterly results |
| 11/12/2013 |
8-K
| Quarterly results |
| 05/08/2013 |
8-K
| Quarterly results|
Docs:
|
"CONSOLIDATED STATEMENTS OF OPERATIONS Three months ended March 31, Nine months ended March 31, 2013 2012 2013 2012 Revenues $ 1,514 $ 1,138 $ 3,373 $ 4,416 Cost of Revenues 674 574 1,451 2,046 Gross Profit 840 564 1,922 2,370 Operating Expenses: Royalties buyout expenses 918 Other research and development expenses 907 1,349 3,109 2,730 Selling and marketing 804 445 2,412 1,373 General and administrative 2,340 1,896 6,341 11,780 Total operating expenses 4,051 3,690 12,780 15,883 Loss from Operations Expenses related to revaluation of contingently redeemable warrants and others, net 402 106 Expenses related to interest on convertible loan and other financial expenses 1,290 3,316 136 Loss before tax expenses Tax Expenses 25 31 7 Net Loss $ $ $ $ Net loss per share – basic and diluted $ ...",
"Investor slide show presentation dated May 2013" |
|
| 11/05/2012 |
8-K
| Quarterly results |
| 05/08/2012 |
8-K
| Quarterly results|
Docs:
|
"InspireMD Announces First Quarter 2012 Financial Results Tel Aviv, Israel – May 8, 2012 – InspireMD, Inc. , a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, today announced financial results for the quarter ended March 31st 2012. Ofir Paz , Co-Founder and CEO of InspireMD, said: “The quarter was marked by continued positive momentum across financial, operational and clinical areas. Demand for MGuardTM increased in the majority of our international markets. We strengthened our senior management, and additional positive data on MGuardTM was reported. We also recently raised gross proceeds of $11 million in a private placement, which strengthened our balance sheet for ..." |
|
| 03/13/2012 |
8-K
| Form 8-K - Current report |
|
|